Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?

2. Holly Energy Partners, L.P.

24.2% sales growth and 32.72% return on equity

Holly Energy Partners, L.P. owns and operates petroleum product and crude pipelines, storage tanks, distribution terminals, loading rack facilities, and refinery processing units that support the refining and marketing operations of HollyFrontier Corporation in West Texas, New Mexico, Utah, Nevada, Oklahoma, Wyoming, Kansas, Arizona, Idaho, and Washington.

Holly Energy Partners, L.P.’s sales growth this year is expected to be 5.5% and 0.7% for next year.

Year-on-year quarterly revenue growth declined by 3.2%, now sitting on 497.85M for the twelve trailing months.

Holly Energy Partners, L.P.’s sales growth is a negative 0% for the ongoing quarter and 24.2% for the next. The company’s growth estimates for the current quarter and the next is 87.5% and negative -32.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.72%.

Volatility

Holly Energy Partners, L.P.’s last day, last week, and last month’s current volatility was 3.18%, 2.38%, and 1.31%, respectively.

Holly Energy Partners, L.P.’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.94% (day), 2.83% (last week), and 2.44% (last month), respectively.

Holly Energy Partners, L.P.’s Stock Yearly Top and Bottom Value

Holly Energy Partners, L.P.’s stock is valued at $21.12 at 17:24 EST, below its 52-week high of $21.47 and way higher than its 52-week low of $10.48.

Holly Energy Partners, L.P.’s Moving Average

Holly Energy Partners, L.P.’s value is higher than its 50-day moving average of $19.55 and way higher than its 200-day moving average of $15.72.

3. Alexion Pharmaceuticals

6.5% sales growth and 4.43% return on equity

Alexion Pharmaceuticals, Inc. develops and commercializes various therapeutic products.

Alexion Pharmaceuticals’s sales growth this year is expected to be 9% and 7.1% for next year.

Year-on-year quarterly revenue growth grew by 13.3%, now sitting on 6.26B for the twelve trailing months.

News about Alexion Pharmaceuticals today

According to today’s article on Bloomberg Quint, "AstraZeneca Plc is confident shareholders will back its $39 billion takeover of rare-disease specialist Alexion Pharmaceuticals Inc. next week as the British company looks to the next chapter of its growth."

Alexion Pharmaceuticals’s sales growth for the next quarter is 6.5%. The company’s growth estimates for the ongoing quarter and the next is 5.1% and 2.8%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.43%.

Volatility

Alexion Pharmaceuticals’s last day, last week, and last month’s current volatility was 0.84%, 1.08%, and 0.91%, respectively.

Alexion Pharmaceuticals’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 0.69% (day), 1.28% (last week), and 0.97% (last month), respectively.

Alexion Pharmaceuticals’s Stock Yearly Top and Bottom Value

Alexion Pharmaceuticals’s stock is valued at $169.91 at 17:24 EST, below its 52-week high of $172.08 and way above its 52-week low of $94.82.

Alexion Pharmaceuticals’s Moving Average

Alexion Pharmaceuticals’s value is above its 50-day moving average of $158.66 and way above its 200-day moving average of $146.52.

Previous days news about Alexion Pharmaceuticals

According to Business Insider on Wednesday, 5 May, "License collaborations with Boehringer Ingelheim and Alexion Pharmaceuticals create opportunity for more patients to potentially benefit from Zealand-invented peptide therapeutics. "

4. Collegium Pharmaceutical

14.4% sales growth and 19.57% return on equity

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, develops and commercializes medicines for pain management.

Collegium Pharmaceutical’s sales growth this year is anticipated to be 9.5% and 10.8% for next year.

Year-on-year quarterly revenue growth grew by 2.8%, now sitting on 310.02M for the twelve trailing months.

Collegium Pharmaceutical’s sales growth for the next quarter is 14.4%. The company’s growth estimates for the ongoing quarter and the next is 2900% and 60.9%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 19.57%.

Volatility

Collegium Pharmaceutical’s last day, last week, and last month’s current volatility was 0.22%, 0.94%, and 1.26%, respectively.

Collegium Pharmaceutical’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 3.67% (day), 2.91% (last week), and 3.85% (last month), respectively.

Collegium Pharmaceutical’s Stock Yearly Top and Bottom Value

Collegium Pharmaceutical’s stock is valued at $22.30 at 17:24 EST, way below its 52-week high of $26.91 and way higher than its 52-week low of $15.66.

Collegium Pharmaceutical’s Moving Average

Collegium Pharmaceutical’s value is below its 50-day moving average of $23.63 and higher than its 200-day moving average of $21.83.

5. Oasis Midstream Partners LP

40.5% sales growth and 11.76% return on equity

Oasis Midstream Partners LP provides crude oil, natural gas, and water-related midstream services in North America.

Oasis Midstream Partners LP’s sales growth this year is anticipated to be 6.9% and a negative 9.8% for next year.

Year-on-year quarterly revenue growth declined by 19.4%, now sitting on 347.86M for the twelve trailing months.

Oasis Midstream Partners LP’s sales growth is a negative 0% for the ongoing quarter and 40.5% for the next. The company’s growth estimates for the ongoing quarter and the next is 5.7% and 153.1%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 11.76%.

Volatility

Oasis Midstream Partners LP’s last day, last week, and last month’s current volatility was 0.81%, 0.92%, and 1.56%, respectively.

Oasis Midstream Partners LP’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.82% (day), 3.42% (last week), and 3.90% (last month), respectively.

Oasis Midstream Partners LP’s Stock Yearly Top and Bottom Value

Oasis Midstream Partners LP’s stock is valued at $20.96 at 17:24 EST, way below its 52-week high of $23.45 and way above its 52-week low of $3.85.

Oasis Midstream Partners LP’s Moving Average

Oasis Midstream Partners LP’s value is below its 50-day moving average of $21.21 and way above its 200-day moving average of $14.98.

6. Brunswick Corporation

29.2% sales growth and 32.13% return on equity

Brunswick Corporation designs, manufactures, and markets recreation products worldwide.

Brunswick Corporation’s sales growth this year is anticipated to be 25.6% and 6.3% for next year.

Year-on-year quarterly revenue growth grew by 48.4%, now sitting on 4.82B for the twelve trailing months.

Brunswick Corporation’s sales growth for the next quarter is 29.2%. The company’s growth estimates for the ongoing quarter and the next is 101% and 7.2%. The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 32.13%.

Volatility

Brunswick Corporation’s last day, last week, and last month’s current volatility was 1.40%, 1.12%, and 1.09%, respectively.

Brunswick Corporation’s current volatility rank, which measures how volatile a financial asset is (variation between the lowest and highest value in a period), was 2.65% (day), 3.28% (last week), and 2.98% (last month), respectively.

Brunswick Corporation’s Stock Yearly Top and Bottom Value

Brunswick Corporation’s stock is valued at $110.86 at 17:24 EST, below its 52-week high of $111.82 and way higher than its 52-week low of $42.78.

Brunswick Corporation’s Moving Average

Brunswick Corporation’s value is higher than its 50-day moving average of $100.81 and way higher than its 200-day moving average of $85.49.

Previous days news about Brunswick Corporation

Brunswick corporation announces date of virtual investor day event. According to Business Insider on Monday, 3 May, "METTAWA, Ill., May 03, 2021 (GLOBE NEWSWIRE) — Brunswick Corporation (NYSE: BC) will host a virtual investor day on May 10, 2021 to provide an update on the Company’s strategic plan and business initiatives, preview some innovative new ACES products and technologies as well as evolving opportunities to engage the new generation of boaters. "

LEAVE A REPLY

Please enter your comment!
Please enter your name here